Evidence Of Severity: Patients at Risk 
Saturday, March 5, 2016: 6:30 PM-8:30 PM
JW Marriott, Platinum Ballroom Level, Salon D
0.00 CME/CE
This program is not sponsored or programmed by the AAAAI.

Sponsored by Teva Respiratory.

This presentation will review the scientific evidence that supports the use of asthma phenotyping and biomarkers in asthma patients. The risks associated with and practical considerations of managing patients with the active eosinophilic airway inflammation phenotype will be discussed. This is a preregistration-only event.